Navigation Links
VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
Date:6/4/2009

ervations suggest DGAT1 inhibitors may have the potential to treat obesity, diabetes and dyslipidemia. VIA intends to identify potential clinical candidates from the compounds in this program and determine whether any can be moved into further preclinical development.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in plaque, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com.

Forward Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements si
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related biology technology :

1. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
5. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
6. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
7. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
9. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
10. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
11. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... ALBANY, N.Y. , June 18, 2013 /PRNewswire/ ... that its Burlington, Mass. , ... U.S. Drug Enforcement Administration (DEA) registration to handle ... represents the DEA,s acknowledgement of Burlington,s ... inventory control and documentation. (Logo: ...
(Date:6/18/2013)...  Techne Corporation (NASDAQ: TECH ) ... acquire 100% ownership of Bionostics Holdings Limited and ... a global leader in the development, manufacture and ... operation of in vitro diagnostic (IVD) ... glucose and blood gas testing.  Biosnostics has strategic ...
(Date:6/18/2013)... Research and Markets ... of the "Injectable Drug Delivery Market ... [Disposables & Reusable, Fillable & Prefilled, Pen, ... [Diabetes & Oncology] - Global Forecasts to ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The ...
(Date:6/18/2013)... June 18, 2013 ... ) has announced the addition of ... & Stable Isotopes Market [SPECT/PET Radioisotopes ... Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, ... report to their offering. ...
Breaking Biology Technology:AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2Techne Corporation Announces Acquisition Agreement 2Techne Corporation Announces Acquisition Agreement 3Techne Corporation Announces Acquisition Agreement 4Techne Corporation Announces Acquisition Agreement 5Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 3
... Enerkem one step closer to becoming the, ... use waste, feedstock,MONTREAL, Jan. 12 /PRNewswire/ ... technology company, announced today that its first commercial-scale plant ... with the production of its clean conditioned synthesis gas. ...
... Biosystems,Inc. (OTC Bulletin Board: WGBS), a leading ... and stem cell research systems, today,announced that ... the company,s SmartChip(TM) Real-Time PCR System in ... testing program. Initial tests,conducted at the ...
... Board of Directors of SemBioSys Genetics Inc. (TSX:SBS), ... plants, today announced that current President and CEO ... position of President and CEO of Botaneco Specialty ... the corporation,s Chief Financial Officer, has been named ...
Cached Biology Technology:Enerkem announces first commercial-scale biofuels and biochemicals plant is entering start-up phase 2Enerkem announces first commercial-scale biofuels and biochemicals plant is entering start-up phase 3WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 2WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 3WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 4WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 5SemBioSys announces senior management changes 2SemBioSys announces senior management changes 3SemBioSys announces senior management changes 4
(Date:6/17/2013)... understand the concept of improving original foundations with more ... the University of Pittsburgh,s Kenneth P. Dietrich School of ... that could make drug delivery, gas storage, and gas ... findings were reported in the latest issue of the ... JACS ). , The recent work builds upon Pitt ...
(Date:6/17/2013)... A Kansas State University research associate has received a ... ways to prevent the spread of malaria. , Bart ... Institutes of Health,s National Research Service Award Individual Postdoctoral ... the seventh Kansas State University researcher to receive the ... currently hold such an award. , Bryant, a university ...
(Date:6/17/2013)... Fracking, the controversial method of mining shale gas, is ... the Appalachian Basin. New research in the Annals ... the threat posed to biodiversity including pollution from toxic ... changes to wetlands. , "Shale gas has engendered a ... on human health, but effects on biological diversity and ...
Breaking Biology News(10 mins):'Chemical architects' build materials with potential applications in drug delivery and gas storage 2NIH fellowship helps researcher fight malaria, understand mosquito immunity 2
... trial launched in Pittsburgh, Pennsylvania today, with sites preparing ... Scientists will test the rectal safety and acceptability of ... has shown promise for preventing HIV through vaginal intercourse. ... gel could be further evaluated to determine if it ...
... its primitive structure, the North American comb jellyfish can ... submarine, making it a successful predator. Researchers, including one ... to show how the jellyfish makes itself hydrodynamically ,invisible,. ... has long been known to consume vast quantities ...
... 2010 A research team at Ben-Gurion University of the ... detected a genetic mutation resulting in a progressive disease of ... research was just published in the American Journal of ... Ohad Birk of the National Institute for Biotechnology in the ...
Cached Biology News:International Rectal Microbicide Advocates cheers launch of world's third rectal microbicide trial 2International Rectal Microbicide Advocates cheers launch of world's third rectal microbicide trial 3Voracious comb jellyfish 'invisible' to prey 2Genetic defect found to cause severe epilepsy and mental retardation 2
... cultured in DMEM and harvested at the log ... the antigens in their native forms, cells were ... on a 12-well (5 mm) adhesive coated slide, ... cellular attachment and to minimize background staining. ...
... CopyControl™ vector can be induced prior to ... provide the stability of single-copy BACs with ... other cloning vectors. The kits provide the ... insert size screening system) necessary to create ...
... / 3T3 cells were cultured in DMEM with ... phase of growth. In order to keep ... fixed in acetone-methanol. The cells are arrayed ... with each wells surface specifically treated to enhance ...
... The CopyControl™ vector can be induced prior ... vectors provide the stability of single-copy BACs ... or other cloning vectors. The kits provide ... reagents, insert size screening system) necessary to ...
Biology Products: